Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageBio-Rad Laboratories, Inc. (referred to in this report as “Bio-Rad,” “we,” “us,” “the Company,” and “our”) is a multinational life science and clinical diagnostics company that develops, manufactures, and markets a broad portfolio of instruments, systems, reagents, and consumables. We have direct operations in over 36 countries outside the United States through subsidiaries focused on sales, customer service, and product distribution.
In the company’s own words · 10-K filed Feb 13, 2026 · SEC EDGAR
Business segments
Q1 2026 · $592.1MThe company’s own SEC segment disclosure.
- US$229.8M39%
- Europe$206.8M35%
- Asia Pacific$110.4M19%
- Americas$45.1M8%
Bio-Rad Laboratories, Inc. (BIO) reported revenue of $592M in Q1 2026 (quarter ended March 31, 2026), up 1.1% from the same quarter a year earlier. That came with a gross margin of 52% and net loss of $527M. For the full year FY2025, revenue was $2.58B (+0.7% year on year) and net income $760M. Its largest region in 2026-Q1 was US at $230M, 39% of the disclosed total, just ahead of Europe at 35%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Medical Devices
Ranks #27 of 35 by Smart Score